We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care

By LabMedica International staff writers
Posted on 08 May 2025

Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. More...

With EDs often being some of the busiest areas in hospitals, this presents significant challenges in quickly diagnosing critical conditions like heart attacks. Now, a new algorithm provides standardized assessments, aiding emergency room physicians in making confident clinical decisions about whether to rule in or rule out heart attacks.

Roche (Basel, Switzerland) has introduced the Chest Pain Triage algorithm, a CE-marked IVD medical device, as part of its navify Algorithm Suite. This suite is a cloud-based platform that hosts clinical algorithms from Roche and its partners, offering labs and hospitals seamless integration with Electronic Health Records (EHR) and Lab Information Systems (LIS), streamlining processes for faster and more efficient operations. Developed by Roche in collaboration with University Hospital Heidelberg (Heidelberg, Germany), the Chest Pain Triage algorithm is specifically designed to detect Acute Coronary Syndrome (ACS) more quickly and accurately in patients presenting with chest pain. The algorithm utilizes cutting-edge diagnostic technologies, including high-sensitivity cardiac troponin testing, to provide healthcare professionals with timely, reliable data to differentiate between cardiac and non-cardiac chest pain.

This advanced algorithm is part of Roche's comprehensive solution for addressing ACS, which also includes the cardiac troponin T Assay and integration with existing lab systems, offering an efficient approach to patient triage in emergency settings. The Chest Pain Triage algorithm is built to align with the European Society of Cardiology’s (ESC) guidelines, with input from top cardiologists and emergency medicine experts who contributed to its development. The algorithm is designed to accurately identify patients who are at genuine risk, distinguishing non-cardiac chest pain cases through a clear Rule-In, Rule-Out, or Observe recommendation based on the ESC guidelines. It simplifies decision-making by automatically selecting the appropriate ESC 0/1, 0/2, or 0/3 accelerated pathways, depending on the timing of the blood sample collection, which has the potential to reduce unnecessary hospital admissions and associated costs.

Additionally, the algorithm speeds up the treatment process for patients with true ACS by providing rapid assessments of chest pain onset, even if it occurred more than three hours before the first blood sample. It also offers a medical dossier to support clinicians and streamlines documentation by allowing easy transfer of recommendations and results into patient records. The Chest Pain Triage algorithm is part of Roche's broader commitment to the early identification and treatment of cardiovascular diseases. It is currently available in Europe, the Middle East, and Asia, with plans for future availability in the United States. Accessible through Roche's navify Algorithm Suite, the algorithm can be integrated into existing emergency department workflows. Roche's cardiometabolic portfolio aims to support quicker and more accurate triage decisions, with future ACS offerings combining next-generation digital algorithms, biomarkers, near-patient care devices, and laboratory analyzers.

"The introduction of our Chest Pain Triage algorithm underscores Roche's commitment to improving care for cardiovascular disease, one of the world’s largest health burdens," said Matt Sause, CEO, Roche Diagnostics. "One of the major challenges in managing chest pain in the emergency department is the length of stay, especially since some patients aren't actually having a heart attack. Our Chest Pain Triage algorithm can help doctors quickly decide who needs urgent cardiac care and who could be discharged sooner. With an early rule-out pathway, we can cut down Emergency Department visit times by over three hours.”


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Troponin T QC
Troponin T Quality Control
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Molecular Diagnostics

view channel
Image: The new study findings emphasize the need for incorporating disease heterogeneity into type 2 diabetes care strategies (Photo courtesy of Cell 2025; doi.org/10.1016/j.cell.2025.05.00)

Molecular Fingerprint for Insulin Sensitivity Could Diagnose Diabetes Before Disease Develops

Insulin is a hormone essential for regulating blood sugar levels, and its dysfunction is a key factor in the development of diabetes. Insulin resistance, a condition where the body's cells do not respond... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.